Anzeige
Mehr »
Samstag, 28.06.2025 - Börsentäglich über 12.000 News

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2AG0F | ISIN: SE0006091997 | Ticker-Symbol: 1YR
Frankfurt
27.06.25 | 08:07
0,014 Euro
-18,02 % -0,003
Branche
Gesundheitswesen
Aktienmarkt
Sonstige
1-Jahres-Chart
IMMUNOVIA AB Chart 1 Jahr
5-Tage-Chart
IMMUNOVIA AB 5-Tage-Chart
PR Newswire
260 Leser
Artikel bewerten:
(1)

Immunovia AB (Publ) presents Nomination Committee

LUND, Sweden, Jan. 8, 2025 /PRNewswire/ -- Immunovia (IMMNOV: Nasdaq Stockholm), the pancreatic cancer diagnostics company, today announced the appointment of the Company's Nomination Committee.

According to the instructions for the Nomination Committee of Immunovia AB (Publ), the Nomination Committee shall consist of four members, of which three should be appointed by the Company's three largest shareholders in terms of votes, and the fourth shall be the Chair of the Board of Directors.

The Nomination Committee will consist of the following persons who together represent 5,65 percent of the number of shares and votes in the Company as of September 30, 2024:

  • Christer Køhler, representing Jens Henrik Jensen
  • Mats Leifland, representing Vincent Saldell
  • Sara Ek, representing Carl Borrebaeck and
  • Peter Høngaard Andersen in his capacity as Chair of the Board of Directors

Jeff Borcherding, the CEO of Immunovia AB, in his capacity as one of the company's largest shareholders, declined the opportunity to appoint a representative to the Nomination Committee in order to ensure the independence of the committee.

The Nomination Committee will prepare proposals for shareholder approval at the 2025 Annual General Meeting (AGM). In particular, the Nomination Committee will nominate candidates for the Immunovia Board of Directors, ensuring the board has the appropriate skills and experience to support the company's success in 2025. The Nomination Committee will also recommend appropriate compensation to be offered to the Board of Directors based on proper benchmarks. Further, the Committee will recommend the election and compensation of the company's auditors.

"It's a pleasure to have the nomination committee in place to start the work leading up to the AGM 2025. It is of vital importance that the competencies of Immunovia's board members reflect the transition of the company's focus from research and development to commercialization in the US," says Peter Høngaard Andersen, Chair of the Board of Directors.

The Nomination Committee's conclusions and proposals will be presented in the notice to the Annual General Meeting 2025, which will be held on May 14, 2025. Further information on the principles and duties of the Nomination Committee can be found at https://investor.immunovia.com/governance/nomination-committee/

For more information, please contact:

Jeff Borcherding
CEO and President
jeff.borcherding@immunovia.com

Karin Almqvist Liwendahl
Chief Financial Officer
karin.almqvist.liwendahl@immunovia.com

The information was submitted for publication, through the agency of the contact persons set out above, at 13:45 CET on January 8, 2025.

Immunovia in brief

Immunovia AB is a diagnostic company whose mission is to increase survival rates for patients with pancreatic cancer through early detection. Immunovia is focused on the development and commercialization of simple blood-based testing to detect proteins and antibodies that indicate a high-risk individual has developed pancreatic cancer. Immunovia collaborates and engages with healthcare providers, leading experts and patient advocacy groups to make its test available to individuals at increased risk for pancreatic cancer.

USA is the world's largest market for detection of pancreatic cancer. The Company estimates that in the USA, 1.8 million individuals are at high-risk for pancreatic cancer and could benefit from annual surveillance testing. Immunovia's shares (IMMNOV) are listed on Nasdaq Stockholm.

For more information, please visit www.immunovia.com.

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/immunovia-ab/r/immunovia-ab--publ--presents-nomination-committee,c4088998

The following files are available for download:

https://mb.cision.com/Main/13121/4088998/3196256.pdf

Press release (PDF)

Cision View original content:https://www.prnewswire.co.uk/news-releases/immunovia-ab-publ-presents-nomination-committee-302345781.html

© 2025 PR Newswire
Zeitenwende! 3 Uranaktien vor der Neubewertung
Ende Mai leitete US-Präsident Donald Trump mit der Unterzeichnung mehrerer Dekrete eine weitreichende Wende in der amerikanischen Energiepolitik ein. Im Fokus: der beschleunigte Ausbau der Kernenergie.

Mit einem umfassenden Maßnahmenpaket sollen Genehmigungsprozesse reformiert, kleinere Reaktoren gefördert und der Anteil von Atomstrom in den USA massiv gesteigert werden. Auslöser ist der explodierende Energiebedarf durch KI-Rechenzentren, der eine stabile, CO₂-arme Grundlastversorgung zwingend notwendig macht.

In unserem kostenlosen Spezialreport erfahren Sie, welche 3 Unternehmen jetzt im Zentrum dieser energiepolitischen Neuausrichtung stehen, und wer vom kommenden Boom der Nuklearindustrie besonders profitieren könnte.

Holen Sie sich den neuesten Report! Verpassen Sie nicht, welche Aktien besonders von der Energiewende in den USA profitieren dürften, und laden Sie sich das Gratis-PDF jetzt kostenlos herunter.

Dieses exklusive Angebot gilt aber nur für kurze Zeit! Daher jetzt downloaden!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.